Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease

SOUTH SAN FRANCISCO, Calif., April 26, 2023 /PRNewswire/ — Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and healthspan, and founded by Alphabet and Arthur D. Levinson Ph.D., today announced that the first participant has been dosed in a…